Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (181-190 of 492) with videos related to

Pageof 50
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension StudyYannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Annals of the Rheumatic Diseases|November 17, 2011
Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosisJérôme Avouac, Christophe Meune, Barbara Ruiz, et al.
Journal of Scleroderma and Related Disorders|February 6, 2023
Challenging diagnosis of renal failure associated with severe neurological symptoms in a patient with mixed connective tissue diseaseClothilde Gros, Olivier Fogel, Idris Boudhabhay, et al.
Respiratory Research|July 25, 2020
The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating diseaseAnna-Maria Hoffmann-Vold, Yannick Allanore, Elisabeth Bendstrup, et al.
Clinical and Experimental Rheumatology|September 1, 2020
Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trialsCosimo Bruni, Donald P Tashkin, Virginia Steen, et al.
BMC Pulmonary Medicine|January 7, 2021
Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case seriesPhilipp Eller, Holger Flick, Gernot Schilcher, et al.
Clinical and Experimental Rheumatology|July 15, 2020
One year in review 2020: systemic sclerosisMartina Orlandi, Gemma Lepri, Arianna Damiani, et al.
Rheumatology (Oxford, England)|August 26, 2023
Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseasesMarion Thomas, Maeva Masson, Samuel Bitoun, et al.
Annals of the Rheumatic Diseases|December 24, 2025
From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosisAlain Lescoat, Yannick Allanore, Francesco Del Galdo, et al.
Drugs in R&D|April 25, 2025
Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)Diamant Thaçi, Sascha Gerdes, Hendrik Schulze-Koops, et al.
Pageof 50

Showing results (181-190 of 492) with videos related to

Sort By:
Pageof 50
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension StudyYannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Annals of the Rheumatic Diseases|November 17, 2011
Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosisJérôme Avouac, Christophe Meune, Barbara Ruiz, et al.
Journal of Scleroderma and Related Disorders|February 6, 2023
Challenging diagnosis of renal failure associated with severe neurological symptoms in a patient with mixed connective tissue diseaseClothilde Gros, Olivier Fogel, Idris Boudhabhay, et al.
Respiratory Research|July 25, 2020
The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating diseaseAnna-Maria Hoffmann-Vold, Yannick Allanore, Elisabeth Bendstrup, et al.
Clinical and Experimental Rheumatology|September 1, 2020
Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trialsCosimo Bruni, Donald P Tashkin, Virginia Steen, et al.
BMC Pulmonary Medicine|January 7, 2021
Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case seriesPhilipp Eller, Holger Flick, Gernot Schilcher, et al.
Clinical and Experimental Rheumatology|July 15, 2020
One year in review 2020: systemic sclerosisMartina Orlandi, Gemma Lepri, Arianna Damiani, et al.
Rheumatology (Oxford, England)|August 26, 2023
Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseasesMarion Thomas, Maeva Masson, Samuel Bitoun, et al.
Annals of the Rheumatic Diseases|December 24, 2025
From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosisAlain Lescoat, Yannick Allanore, Francesco Del Galdo, et al.
Drugs in R&D|April 25, 2025
Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)Diamant Thaçi, Sascha Gerdes, Hendrik Schulze-Koops, et al.
Pageof 50